Pfizer gets new rebuff from UK cost body for cancer drug
LONDON (Reuters) - Pfizer suffered a second rejection in two days from Britain's health cost watchdog NICE as its new kidney cancer drug Inlyta was turned down for use on the state health service.
The National Institute for Health and Clinical Excellence (NICE) said on Thursday the new treatment was not a cost-effective use of National Health Service resources.
The decision follows a similar rebuff for Pfizer's lung cancer drug Xalkori on Wednesday.
In both cases, the NICE recommendations are preliminary and subject to further consultation.
- Malaysia Airlines denies crash report, says plane still missing |
- UPDATE 4-Malaysia Airlines plane crashes in South China Sea with 239 people aboard - report
- China draws red line' on North Korea, says won't allow war on peninsula
- No signal picked up from missing Malaysia Airlines plane-Vietnam official
- Malaysian plane crashed off Vietnam coast: state media